Vaccine and Pharmaceutical Technologies

Improving vaccine and pharmaceutical products and impact in developing countries

Technology Solutions Global ProgramAs part of PATH’s Technology Solutions Global Program, our work in vaccine and pharmaceutical technologies extends across three interrelated technical portfolios with more than 30 years of experience in product formulation and stabilization, delivery devices, and supply systems and equipment for low-resource settings. Learn more »

Strategies to Prevent Vaccine Freezing video

Watch our freeze-prevention film on YouTube.

This 4-minute animated film emphasizes the difficulty and importance of maintaining proper temperatures in the vaccine cold chain. It also discusses the risks of exposing vaccines to freezing temperatures and a range of different approaches to reducing these risks. Watch the video on PATH’s YouTube channel.

News and highlights

TECHNICAL RESOURCE: A new dossier describes PATH’s low-cost, straightforward approach for protecting aluminum-adjuvanted vaccines from freeze damage »

JOURNAL ARTICLE: Development of a fast-dissolving tablet formulation of Newcastle disease vaccine »

PUBLICATION: Giving smaller doses of yellow fever vaccine could help increase vaccine supply and availability in countries most affected by the disease »

Sign up for our e-newsletter

Sign up for our e-newsletter.The e-newsletter, Vaccine and Pharmaceutical Technologies News and Updates, provides semiannual briefings and related resources on our work to advance technologies that improve vaccine and pharmaceutical products and the way they are delivered, especially in low-resource settings. Sign up now »

Visit the Vaccine Resource Library

PATH’s Vaccine Resource Library (VRL) contains key immunization resources in a single, easy-to-use website. The VRL offers links to scientific publications and high-quality, technical summaries on specific diseases and topics in immunization. To learn more, visit the VRL »

Banner photos, clockwise from left: PATH/Patrick McKern; PATH/Gabe Bienczycki; PATH/Mike Wang.

Comments are closed.